Crossmark

Pharmacological HIF activation protects against diet-induced obesity, glucose intolerance, and skeletal dysfunction by exerting dual beneficial effects on energy metabolism and bone

Crossref DOI link: https://doi.org/10.1038/s41413-025-00503-3

Published Online: 2026-02-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Valle-Tenney, Roger

Peredo, Nicolas https://orcid.org/0000-0002-4670-3700
De Samblancx, Karen

Nefyodova, Elena

Cardoen, Ruben

Dehaemers, Tom

Farlay, Delphine

Chapurlat, Roland

Van der Schueren, Bart

Mathieu, Chantal

Vangoitsenhoven, Roman https://orcid.org/0000-0003-3523-669X
Maes, Christa https://orcid.org/0000-0003-4243-5486
Funding

Funding for this research was provided by:

Fonds Wetenschappelijk Onderzoek (G0B5219N)

Fonds Wetenschappelijk Onderzoek (1291522N)

Fonds Wetenschappelijk Onderzoek (1S03417N)

Fonds Wetenschappelijk Onderzoek (1291522N)

Fonds Wetenschappelijk Onderzoek (1S03417N)
License Information

Text and Data Mining valid from 2026-02-11

Version of Record valid from 2026-02-11
More Information

Article History

Received: 20 May 2025

Revised: 6 November 2025

Accepted: 30 November 2025

First Online: 11 February 2026

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below